Source: Eur Respir J 2009; 34: 1159-1167
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Tabata C., Tabata R., Hirayama N., Yasumitsu A., Yamada S., Murakami A., Iida S., Tamura K., Terada T., Kuribayashi K., Fukuoka K., Nakano T.. All-trans-retinoic acid inhibits tumour growth of malignant pleural mesothelioma in mice. Eur Respir J 2009; 34: 1159-1167

Member's Comments

No comment yet.

Related content which might interest you: All-trans-retinoic acid inhibits tumor growth of malignant pleural mesothelioma in mice Source: Annual Congress 2010 - Basic mechanisms in malignant pleural disease biology Year: 2010 A novel clinical role for angiopoietin-1 in malignant pleural mesothelioma Source: Eur Respir J 2010; 36: 1099-1105 Year: 2010 Targeting of CSF1R abrogates Lewis Lung adenocarcinoma-induced malignant pleural effusion Source: International Congress 2018 – Mesothelioma and pleural malignancy: investigations and management Year: 2018 Talc mediates angiostasis in malignant pleural effusions via endostatin induction Source: Eur Respir J 2007; 29: 761-769 Year: 2007 Interleukin-8 and other mediators are related to tumour burden in malignant pleural effusions (MPE) Source: Eur Respir J 2007; 30: Suppl. 51, 103s Year: 2007 The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Prognostic role of inflammatory cells in blood, pleural fluid and tumour samples, in patients with malignant pleural mesothelioma (MPM) Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 Novel Synthetic lignan reduces asbestos-induced damage in human pleural mesothelial cells-Potential clinical usefulness in inhibiting pleural malignant mesothelioma Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Bevacizumab-targeted therapy for malignant pleural mesothelioma Source: International Congress 2017 – Malignant pleural effusion management in 2017: a review of recent RCTs Year: 2017 Zoledronic acid limits experimental malignant pleural effusion Source: Eur Respir J 2007; 30: Suppl. 51, 435s Year: 2007 Alteration of neutrophil invasion toward malignant mesothelioma by Interleukin-10 Source: Eur Respir J 2002; 20: Suppl. 38, 231s Year: 2002 CXCL12 expression in malignant mesothelioma Source: Eur Respir J 2007; 30: Suppl. 51, 138s Year: 2007 Effects of cisplatin and pemetrexed on 3D phenotypes of benign mesothelial and malignant pleural mesothelioma cells Source: International Congress 2018 – Clinical management of pleural malignancies, including mesothelioma Year: 2018 Malignant pleural effusion cells show aberrant glucose metabolism gene expression Source: Eur Respir J 2011; 37: 1453-1465 Year: 2011 Cytological diagnosis of malignant mesothelioma – improvement by additional determination of hyaluronic acid in pleural effusions Source: Eur Respir J 2006; 28: Suppl. 50, 783s Year: 2006 mTOR inhibition blocks tumor growth and pleural fluid accumulation in experimental murine mesothelioma Source: Annual Congress 2011 - Treatment options and tumour biology of malignant pleural mesothelioma Year: 2011 Frequent epidermal growth factor receptor gene mutations in malignant pleural effusion of lung adenocarcinoma Source: Eur Respir J 2008; 32: 924-930 Year: 2008 Host-derived osteopontin is important for malignant pleural effusion formation Source: Annual Congress 2008 - Novel trends in functional genomics and molecular pathology of neoplastic and non-neoplastic lung diseases Year: 2008 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012